nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—colon cancer	0.282	1	CiPCiCtD
Pemetrexed—Methotrexate—colon cancer	0.186	1	CrCtD
Pemetrexed—lung cancer—colon cancer	0.141	1	CtDrD
Pemetrexed—TYMS—colon cancer	0.0963	1	CbGaD
Pemetrexed—TYMS—Capecitabine—colon cancer	0.0278	0.213	CbGbCtD
Pemetrexed—ATIC—Methotrexate—colon cancer	0.0257	0.197	CbGbCtD
Pemetrexed—Raltitrexed—Methotrexate—colon cancer	0.0246	0.2	CrCrCtD
Pemetrexed—Pralatrexate—Methotrexate—colon cancer	0.0246	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—colon cancer	0.0246	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—colon cancer	0.0246	0.2	CrCrCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—colon cancer	0.0246	0.2	CrCrCtD
Pemetrexed—SLC46A1—Methotrexate—colon cancer	0.0204	0.157	CbGbCtD
Pemetrexed—SLC29A1—Fluorouracil—colon cancer	0.0178	0.137	CbGbCtD
Pemetrexed—TYMS—Fluorouracil—colon cancer	0.0165	0.126	CbGbCtD
Pemetrexed—DHFR—Methotrexate—colon cancer	0.0131	0.1	CbGbCtD
Pemetrexed—TYMS—Methotrexate—colon cancer	0.0091	0.0697	CbGbCtD
Pemetrexed—GART—renal system—colon cancer	0.00046	0.0454	CbGeAlD
Pemetrexed—GART—One Carbon Metabolism—TYMS—colon cancer	0.000457	0.074	CbGpPWpGaD
Pemetrexed—ATIC—embryo—colon cancer	0.000413	0.0407	CbGeAlD
Pemetrexed—GART—lymphoid tissue—colon cancer	0.000382	0.0377	CbGeAlD
Pemetrexed—GART—digestive system—colon cancer	0.000377	0.0372	CbGeAlD
Pemetrexed—GART—bone marrow—colon cancer	0.000348	0.0343	CbGeAlD
Pemetrexed—DCK—Topotecan—Irinotecan—colon cancer	0.000343	0.636	CbGdCrCtD
Pemetrexed—ATIC—epithelium—colon cancer	0.000337	0.0332	CbGeAlD
Pemetrexed—GART—vagina—colon cancer	0.000333	0.0329	CbGeAlD
Pemetrexed—ATIC—smooth muscle tissue—colon cancer	0.000325	0.032	CbGeAlD
Pemetrexed—ATIC—One Carbon Metabolism—TYMS—colon cancer	0.000317	0.0513	CbGpPWpGaD
Pemetrexed—Raltitrexed—TYMS—colon cancer	0.000316	0.341	CrCbGaD
Pemetrexed—ATIC—renal system—colon cancer	0.000312	0.0308	CbGeAlD
Pemetrexed—SLC46A1—lymphoid tissue—colon cancer	0.00031	0.0306	CbGeAlD
Pemetrexed—SLC46A1—digestive system—colon cancer	0.000306	0.0302	CbGeAlD
Pemetrexed—GART—liver—colon cancer	0.000281	0.0277	CbGeAlD
Pemetrexed—DHFR—embryo—colon cancer	0.000277	0.0274	CbGeAlD
Pemetrexed—ATIC—lymphoid tissue—colon cancer	0.000259	0.0256	CbGeAlD
Pemetrexed—ATIC—digestive system—colon cancer	0.000256	0.0253	CbGeAlD
Pemetrexed—DCK—embryo—colon cancer	0.00024	0.0237	CbGeAlD
Pemetrexed—Leucovorin—TYMS—colon cancer	0.000239	0.258	CrCbGaD
Pemetrexed—Pralatrexate—TYMS—colon cancer	0.000239	0.258	CrCbGaD
Pemetrexed—SLC46A1—liver—colon cancer	0.000228	0.0225	CbGeAlD
Pemetrexed—TYMS—smooth muscle tissue—colon cancer	0.00022	0.0217	CbGeAlD
Pemetrexed—GART—lymph node—colon cancer	0.000216	0.0213	CbGeAlD
Pemetrexed—DHFR—renal system—colon cancer	0.00021	0.0207	CbGeAlD
Pemetrexed—GART—Nucleotide metabolism—TYMS—colon cancer	0.000202	0.0326	CbGpPWpGaD
Pemetrexed—DHFR—G1/S-Specific Transcription—TYMS—colon cancer	0.000197	0.0319	CbGpPWpGaD
Pemetrexed—ATIC—liver—colon cancer	0.000191	0.0188	CbGeAlD
Pemetrexed—SLC29A1—renal system—colon cancer	0.00019	0.0188	CbGeAlD
Pemetrexed—DCK—Pyrimidine metabolism—TYMS—colon cancer	0.000186	0.0301	CbGpPWpGaD
Pemetrexed—TYMS—lymphoid tissue—colon cancer	0.000176	0.0174	CbGeAlD
Pemetrexed—SLC46A1—lymph node—colon cancer	0.000175	0.0173	CbGeAlD
Pemetrexed—DHFR—lymphoid tissue—colon cancer	0.000174	0.0172	CbGeAlD
Pemetrexed—TYMS—digestive system—colon cancer	0.000174	0.0171	CbGeAlD
Pemetrexed—DHFR—digestive system—colon cancer	0.000172	0.017	CbGeAlD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—TYMS—colon cancer	0.000172	0.0278	CbGpPWpGaD
Pemetrexed—TYMS—bone marrow—colon cancer	0.00016	0.0158	CbGeAlD
Pemetrexed—DHFR—bone marrow—colon cancer	0.000159	0.0157	CbGeAlD
Pemetrexed—SLC29A1—lymphoid tissue—colon cancer	0.000158	0.0156	CbGeAlD
Pemetrexed—SLC29A1—digestive system—colon cancer	0.000156	0.0154	CbGeAlD
Pemetrexed—TYMS—vagina—colon cancer	0.000153	0.0151	CbGeAlD
Pemetrexed—DHFR—vagina—colon cancer	0.000152	0.015	CbGeAlD
Pemetrexed—DCK—lymphoid tissue—colon cancer	0.000151	0.0149	CbGeAlD
Pemetrexed—DCK—digestive system—colon cancer	0.000149	0.0147	CbGeAlD
Pemetrexed—ATIC—lymph node—colon cancer	0.000146	0.0144	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—colon cancer	0.000144	0.0142	CbGeAlD
Pemetrexed—ATIC—Nucleotide metabolism—TYMS—colon cancer	0.00014	0.0226	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.00014	0.0226	CbGpPWpGaD
Pemetrexed—SLC29A1—vagina—colon cancer	0.000138	0.0136	CbGeAlD
Pemetrexed—DCK—bone marrow—colon cancer	0.000137	0.0135	CbGeAlD
Pemetrexed—DHFR—One Carbon Metabolism—TYMS—colon cancer	0.000132	0.0214	CbGpPWpGaD
Pemetrexed—DCK—vagina—colon cancer	0.000131	0.013	CbGeAlD
Pemetrexed—TYMS—liver—colon cancer	0.000129	0.0128	CbGeAlD
Pemetrexed—DHFR—liver—colon cancer	0.000128	0.0126	CbGeAlD
Pemetrexed—DHFR—Trans-sulfuration and one carbon metabolism—TYMS—colon cancer	0.000119	0.0192	CbGpPWpGaD
Pemetrexed—TYMS—Vinorelbine—Vincristine—colon cancer	0.000116	0.216	CbGdCrCtD
Pemetrexed—GART—Metabolism—CA7—colon cancer	0.000116	0.0188	CbGpPWpGaD
Pemetrexed—DHFR—E2F mediated regulation of DNA replication—TYMS—colon cancer	0.000116	0.0188	CbGpPWpGaD
Pemetrexed—DHFR—Fluoropyrimidine Activity—TYMS—colon cancer	0.000116	0.0188	CbGpPWpGaD
Pemetrexed—SLC29A1—liver—colon cancer	0.000116	0.0115	CbGeAlD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.000112	0.0181	CbGpPWpGaD
Pemetrexed—DCK—liver—colon cancer	0.000111	0.0109	CbGeAlD
Pemetrexed—Methotrexate—TYMS—colon cancer	0.000105	0.114	CrCbGaD
Pemetrexed—TYMS—lymph node—colon cancer	9.93e-05	0.0098	CbGeAlD
Pemetrexed—DHFR—lymph node—colon cancer	9.83e-05	0.0097	CbGeAlD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	9.79e-05	0.0158	CbGpPWpGaD
Pemetrexed—SLC29A1—lymph node—colon cancer	8.9e-05	0.00878	CbGeAlD
Pemetrexed—DCK—lymph node—colon cancer	8.5e-05	0.00839	CbGeAlD
Pemetrexed—ATIC—Metabolism—CA7—colon cancer	8.07e-05	0.0131	CbGpPWpGaD
Pemetrexed—TYMS—Vinblastine—Vincristine—colon cancer	8.01e-05	0.148	CbGdCrCtD
Pemetrexed—GART—Folate Metabolism—TP53—colon cancer	7.64e-05	0.0124	CbGpPWpGaD
Pemetrexed—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—colon cancer	7.31e-05	0.0118	CbGpPWpGaD
Pemetrexed—DCK—Nucleotide metabolism—TYMS—colon cancer	7.26e-05	0.0117	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	7.07e-05	0.0114	CbGpPWpGaD
Pemetrexed—GART—Metabolism—ODC1—colon cancer	7.05e-05	0.0114	CbGpPWpGaD
Pemetrexed—GART—Metabolism—CHST5—colon cancer	7.05e-05	0.0114	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TOP1—colon cancer	6.78e-05	0.011	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TYMS—colon cancer	6.65e-05	0.0108	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CA7—colon cancer	6.29e-05	0.0102	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—TYMS—colon cancer	6.15e-05	0.00995	CbGpPWpGaD
Pemetrexed—Pancytopenia—Vincristine—colon cancer	6.04e-05	0.00263	CcSEcCtD
Pemetrexed—Oesophagitis—Capecitabine—colon cancer	6.03e-05	0.00263	CcSEcCtD
Pemetrexed—Angina pectoris—Irinotecan—colon cancer	6.03e-05	0.00263	CcSEcCtD
Pemetrexed—Neutropenia—Vincristine—colon cancer	5.94e-05	0.00259	CcSEcCtD
Pemetrexed—Dysphagia—Fluorouracil—colon cancer	5.93e-05	0.00259	CcSEcCtD
Pemetrexed—Neutropenia—Irinotecan—colon cancer	5.79e-05	0.00253	CcSEcCtD
Pemetrexed—Angina pectoris—Fluorouracil—colon cancer	5.77e-05	0.00252	CcSEcCtD
Pemetrexed—Sepsis—Capecitabine—colon cancer	5.73e-05	0.0025	CcSEcCtD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—TP53—colon cancer	5.7e-05	0.00921	CbGpPWpGaD
Pemetrexed—Pancytopenia—Fluorouracil—colon cancer	5.63e-05	0.00246	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Vincristine—colon cancer	5.59e-05	0.00244	CcSEcCtD
Pemetrexed—SLC46A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	5.56e-05	0.00899	CbGpPWpGaD
Pemetrexed—Neuropathy peripheral—Vincristine—colon cancer	5.55e-05	0.00242	CcSEcCtD
Pemetrexed—Myocardial infarction—Vincristine—colon cancer	5.55e-05	0.00242	CcSEcCtD
Pemetrexed—Stomatitis—Vincristine—colon cancer	5.52e-05	0.00241	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Irinotecan—colon cancer	5.44e-05	0.00237	CcSEcCtD
Pemetrexed—Renal failure—Irinotecan—colon cancer	5.42e-05	0.00237	CcSEcCtD
Pemetrexed—Myocardial infarction—Irinotecan—colon cancer	5.41e-05	0.00236	CcSEcCtD
Pemetrexed—Stomatitis—Irinotecan—colon cancer	5.38e-05	0.00235	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TYMS—colon cancer	5.35e-05	0.00865	CbGpPWpGaD
Pemetrexed—Haemolytic anaemia—Capecitabine—colon cancer	5.31e-05	0.00232	CcSEcCtD
Pemetrexed—Infestation—Fluorouracil—colon cancer	5.29e-05	0.00231	CcSEcCtD
Pemetrexed—Infestation NOS—Fluorouracil—colon cancer	5.29e-05	0.00231	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Fluorouracil—colon cancer	5.21e-05	0.00227	CcSEcCtD
Pemetrexed—Renal failure acute—Capecitabine—colon cancer	5.19e-05	0.00227	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Fluorouracil—colon cancer	5.18e-05	0.00226	CcSEcCtD
Pemetrexed—Myocardial infarction—Fluorouracil—colon cancer	5.18e-05	0.00226	CcSEcCtD
Pemetrexed—Stomatitis—Fluorouracil—colon cancer	5.15e-05	0.00225	CcSEcCtD
Pemetrexed—Conjunctivitis—Fluorouracil—colon cancer	5.14e-05	0.00224	CcSEcCtD
Pemetrexed—DHFR—Metabolism of nitric oxide—AKT1—colon cancer	5.06e-05	0.00818	CbGpPWpGaD
Pemetrexed—Urinary tract disorder—Vincristine—colon cancer	5.02e-05	0.00219	CcSEcCtD
Pemetrexed—Respiratory failure—Methotrexate—colon cancer	5.01e-05	0.00218	CcSEcCtD
Pemetrexed—Urethral disorder—Vincristine—colon cancer	4.99e-05	0.00218	CcSEcCtD
Pemetrexed—Agranulocytosis—Fluorouracil—colon cancer	4.93e-05	0.00215	CcSEcCtD
Pemetrexed—Pulmonary embolism—Methotrexate—colon cancer	4.92e-05	0.00215	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Capecitabine—colon cancer	4.89e-05	0.00213	CcSEcCtD
Pemetrexed—ATIC—Metabolism—CHST5—colon cancer	4.89e-05	0.00791	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ODC1—colon cancer	4.89e-05	0.00791	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	4.82e-05	0.0078	CbGpPWpGaD
Pemetrexed—Pharyngitis—Fluorouracil—colon cancer	4.71e-05	0.00206	CcSEcCtD
Pemetrexed—Skin exfoliation—Methotrexate—colon cancer	4.69e-05	0.00205	CcSEcCtD
Pemetrexed—SLC46A1—Disease—CHST5—colon cancer	4.55e-05	0.00736	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—LGR5—colon cancer	4.55e-05	0.00736	CbGpPWpGaD
Pemetrexed—Mood swings—Capecitabine—colon cancer	4.54e-05	0.00198	CcSEcCtD
Pemetrexed—Alopecia—Vincristine—colon cancer	4.5e-05	0.00196	CcSEcCtD
Pemetrexed—Blood creatinine increased—Capecitabine—colon cancer	4.49e-05	0.00196	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—TYMS—colon cancer	4.46e-05	0.00722	CbGpPWpGaD
Pemetrexed—Dehydration—Capecitabine—colon cancer	4.46e-05	0.00195	CcSEcCtD
Pemetrexed—Arrhythmia—Irinotecan—colon cancer	4.43e-05	0.00193	CcSEcCtD
Pemetrexed—Alopecia—Irinotecan—colon cancer	4.38e-05	0.00191	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Capecitabine—colon cancer	4.32e-05	0.00188	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Capecitabine—colon cancer	4.32e-05	0.00188	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—MLH3—colon cancer	4.3e-05	0.00695	CbGpPWpGaD
Pemetrexed—Sepsis—Methotrexate—colon cancer	4.27e-05	0.00186	CcSEcCtD
Pemetrexed—Arrhythmia—Fluorouracil—colon cancer	4.24e-05	0.00185	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Capecitabine—colon cancer	4.23e-05	0.00184	CcSEcCtD
Pemetrexed—DCK—Metabolism—CA7—colon cancer	4.2e-05	0.00678	CbGpPWpGaD
Pemetrexed—Alopecia—Fluorouracil—colon cancer	4.19e-05	0.00183	CcSEcCtD
Pemetrexed—Dysphagia—Capecitabine—colon cancer	4.14e-05	0.00181	CcSEcCtD
Pemetrexed—Erythema—Fluorouracil—colon cancer	4.13e-05	0.0018	CcSEcCtD
Pemetrexed—SLC46A1—Folate Metabolism—TP53—colon cancer	4.13e-05	0.00667	CbGpPWpGaD
Pemetrexed—Anaemia—Vincristine—colon cancer	4.09e-05	0.00179	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	4.06e-05	0.00656	CbGpPWpGaD
Pemetrexed—Angina pectoris—Capecitabine—colon cancer	4.04e-05	0.00176	CcSEcCtD
Pemetrexed—Anaemia—Irinotecan—colon cancer	3.99e-05	0.00174	CcSEcCtD
Pemetrexed—Leukopenia—Vincristine—colon cancer	3.96e-05	0.00173	CcSEcCtD
Pemetrexed—Pancytopenia—Capecitabine—colon cancer	3.93e-05	0.00172	CcSEcCtD
Pemetrexed—Neutropenia—Capecitabine—colon cancer	3.87e-05	0.00169	CcSEcCtD
Pemetrexed—Syncope—Irinotecan—colon cancer	3.87e-05	0.00169	CcSEcCtD
Pemetrexed—Renal failure acute—Methotrexate—colon cancer	3.86e-05	0.00169	CcSEcCtD
Pemetrexed—Leukopenia—Irinotecan—colon cancer	3.86e-05	0.00168	CcSEcCtD
Pemetrexed—DHFR—Fluoropyrimidine Activity—TP53—colon cancer	3.85e-05	0.00623	CbGpPWpGaD
Pemetrexed—Hypertension—Vincristine—colon cancer	3.82e-05	0.00167	CcSEcCtD
Pemetrexed—Anaemia—Fluorouracil—colon cancer	3.82e-05	0.00167	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—ODC1—colon cancer	3.81e-05	0.00616	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CHST5—colon cancer	3.81e-05	0.00616	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Irinotecan—colon cancer	3.79e-05	0.00165	CcSEcCtD
Pemetrexed—Myalgia—Vincristine—colon cancer	3.77e-05	0.00165	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—TYMS—colon cancer	3.76e-05	0.00608	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MLH3—colon cancer	3.75e-05	0.00607	CbGpPWpGaD
Pemetrexed—Hypertension—Irinotecan—colon cancer	3.72e-05	0.00163	CcSEcCtD
Pemetrexed—Leukopenia—Fluorouracil—colon cancer	3.7e-05	0.00161	CcSEcCtD
Pemetrexed—Infestation NOS—Capecitabine—colon cancer	3.69e-05	0.00161	CcSEcCtD
Pemetrexed—Infestation—Capecitabine—colon cancer	3.69e-05	0.00161	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Capecitabine—colon cancer	3.66e-05	0.0016	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Capecitabine—colon cancer	3.64e-05	0.00159	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Methotrexate—colon cancer	3.64e-05	0.00159	CcSEcCtD
Pemetrexed—Renal failure—Capecitabine—colon cancer	3.63e-05	0.00158	CcSEcCtD
Pemetrexed—Myocardial infarction—Capecitabine—colon cancer	3.62e-05	0.00158	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Capecitabine—colon cancer	3.62e-05	0.00158	CcSEcCtD
Pemetrexed—Oedema—Vincristine—colon cancer	3.61e-05	0.00158	CcSEcCtD
Pemetrexed—Anaphylactic shock—Vincristine—colon cancer	3.61e-05	0.00158	CcSEcCtD
Pemetrexed—Stomatitis—Capecitabine—colon cancer	3.6e-05	0.00157	CcSEcCtD
Pemetrexed—Infection—Vincristine—colon cancer	3.59e-05	0.00157	CcSEcCtD
Pemetrexed—Conjunctivitis—Capecitabine—colon cancer	3.59e-05	0.00157	CcSEcCtD
Pemetrexed—Nervous system disorder—Vincristine—colon cancer	3.54e-05	0.00155	CcSEcCtD
Pemetrexed—Thrombocytopenia—Vincristine—colon cancer	3.54e-05	0.00154	CcSEcCtD
Pemetrexed—Anaphylactic shock—Irinotecan—colon cancer	3.52e-05	0.00154	CcSEcCtD
Pemetrexed—Oedema—Irinotecan—colon cancer	3.52e-05	0.00154	CcSEcCtD
Pemetrexed—Chest pain—Fluorouracil—colon cancer	3.52e-05	0.00153	CcSEcCtD
Pemetrexed—Myalgia—Fluorouracil—colon cancer	3.52e-05	0.00153	CcSEcCtD
Pemetrexed—Infection—Irinotecan—colon cancer	3.5e-05	0.00153	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Capecitabine—colon cancer	3.49e-05	0.00152	CcSEcCtD
Pemetrexed—Shock—Irinotecan—colon cancer	3.46e-05	0.00151	CcSEcCtD
Pemetrexed—Nervous system disorder—Irinotecan—colon cancer	3.45e-05	0.00151	CcSEcCtD
Pemetrexed—Agranulocytosis—Capecitabine—colon cancer	3.45e-05	0.0015	CcSEcCtD
Pemetrexed—Thrombocytopenia—Irinotecan—colon cancer	3.45e-05	0.0015	CcSEcCtD
Pemetrexed—Anorexia—Vincristine—colon cancer	3.45e-05	0.0015	CcSEcCtD
Pemetrexed—Mood swings—Methotrexate—colon cancer	3.38e-05	0.00148	CcSEcCtD
Pemetrexed—DHFR—Metabolism—CA7—colon cancer	3.37e-05	0.00545	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Fluorouracil—colon cancer	3.37e-05	0.00147	CcSEcCtD
Pemetrexed—Oedema—Fluorouracil—colon cancer	3.37e-05	0.00147	CcSEcCtD
Pemetrexed—TYMS—Fluoropyrimidine Activity—TP53—colon cancer	3.36e-05	0.00543	CbGpPWpGaD
Pemetrexed—Anorexia—Irinotecan—colon cancer	3.36e-05	0.00146	CcSEcCtD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	3.35e-05	0.00542	CbGpPWpGaD
Pemetrexed—Infection—Fluorouracil—colon cancer	3.35e-05	0.00146	CcSEcCtD
Pemetrexed—Hepatitis—Capecitabine—colon cancer	3.32e-05	0.00145	CcSEcCtD
Pemetrexed—Nervous system disorder—Fluorouracil—colon cancer	3.31e-05	0.00144	CcSEcCtD
Pemetrexed—Thrombocytopenia—Fluorouracil—colon cancer	3.3e-05	0.00144	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Vincristine—colon cancer	3.29e-05	0.00144	CcSEcCtD
Pemetrexed—Pharyngitis—Capecitabine—colon cancer	3.29e-05	0.00144	CcSEcCtD
Pemetrexed—Urinary tract disorder—Capecitabine—colon cancer	3.27e-05	0.00143	CcSEcCtD
Pemetrexed—SLC46A1—Disease—AXIN2—colon cancer	3.27e-05	0.00528	CbGpPWpGaD
Pemetrexed—Urethral disorder—Capecitabine—colon cancer	3.25e-05	0.00142	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	3.24e-05	0.00525	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	3.24e-05	0.00524	CbGpPWpGaD
Pemetrexed—Anorexia—Fluorouracil—colon cancer	3.21e-05	0.0014	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Methotrexate—colon cancer	3.21e-05	0.0014	CcSEcCtD
Pemetrexed—Decreased appetite—Vincristine—colon cancer	3.14e-05	0.00137	CcSEcCtD
Pemetrexed—Dyspnoea—Irinotecan—colon cancer	3.14e-05	0.00137	CcSEcCtD
Pemetrexed—Erythema multiforme—Capecitabine—colon cancer	3.14e-05	0.00137	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Vincristine—colon cancer	3.12e-05	0.00136	CcSEcCtD
Pemetrexed—Fatigue—Vincristine—colon cancer	3.12e-05	0.00136	CcSEcCtD
Pemetrexed—Eye disorder—Capecitabine—colon cancer	3.1e-05	0.00135	CcSEcCtD
Pemetrexed—Dyspepsia—Irinotecan—colon cancer	3.1e-05	0.00135	CcSEcCtD
Pemetrexed—Constipation—Vincristine—colon cancer	3.09e-05	0.00135	CcSEcCtD
Pemetrexed—Pain—Vincristine—colon cancer	3.09e-05	0.00135	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Fluorouracil—colon cancer	3.07e-05	0.00134	CcSEcCtD
Pemetrexed—Decreased appetite—Irinotecan—colon cancer	3.06e-05	0.00134	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Irinotecan—colon cancer	3.04e-05	0.00133	CcSEcCtD
Pemetrexed—Fatigue—Irinotecan—colon cancer	3.03e-05	0.00132	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—colon cancer	3.02e-05	0.00132	CcSEcCtD
Pemetrexed—Constipation—Irinotecan—colon cancer	3.01e-05	0.00131	CcSEcCtD
Pemetrexed—Pain—Irinotecan—colon cancer	3.01e-05	0.00131	CcSEcCtD
Pemetrexed—Dyspnoea—Fluorouracil—colon cancer	3.01e-05	0.00131	CcSEcCtD
Pemetrexed—DHFR—E2F transcription factor network—CDKN1A—colon cancer	3e-05	0.00485	CbGpPWpGaD
Pemetrexed—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	2.98e-05	0.00482	CbGpPWpGaD
Pemetrexed—Dyspepsia—Fluorouracil—colon cancer	2.97e-05	0.0013	CcSEcCtD
Pemetrexed—Arrhythmia—Capecitabine—colon cancer	2.96e-05	0.00129	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Vincristine—colon cancer	2.96e-05	0.00129	CcSEcCtD
Pemetrexed—TYMS—Metabolism—CA7—colon cancer	2.94e-05	0.00476	CbGpPWpGaD
Pemetrexed—Decreased appetite—Fluorouracil—colon cancer	2.93e-05	0.00128	CcSEcCtD
Pemetrexed—Alopecia—Capecitabine—colon cancer	2.93e-05	0.00128	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—colon cancer	2.93e-05	0.00128	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Fluorouracil—colon cancer	2.91e-05	0.00127	CcSEcCtD
Pemetrexed—Erythema—Capecitabine—colon cancer	2.89e-05	0.00126	CcSEcCtD
Pemetrexed—Malnutrition—Capecitabine—colon cancer	2.89e-05	0.00126	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—colon cancer	2.88e-05	0.00126	CcSEcCtD
Pemetrexed—Pain—Fluorouracil—colon cancer	2.88e-05	0.00126	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Irinotecan—colon cancer	2.88e-05	0.00126	CcSEcCtD
Pemetrexed—Abdominal pain—Vincristine—colon cancer	2.86e-05	0.00125	CcSEcCtD
Pemetrexed—Body temperature increased—Vincristine—colon cancer	2.86e-05	0.00125	CcSEcCtD
Pemetrexed—DHFR—E2F transcription factor network—EP300—colon cancer	2.85e-05	0.00461	CbGpPWpGaD
Pemetrexed—Dysgeusia—Capecitabine—colon cancer	2.83e-05	0.00123	CcSEcCtD
Pemetrexed—Body temperature increased—Irinotecan—colon cancer	2.78e-05	0.00121	CcSEcCtD
Pemetrexed—Abdominal pain—Irinotecan—colon cancer	2.78e-05	0.00121	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—colon cancer	2.75e-05	0.0012	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—colon cancer	2.75e-05	0.0012	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—colon cancer	2.73e-05	0.00119	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—colon cancer	2.7e-05	0.00118	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	2.69e-05	0.00435	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MYC—colon cancer	2.69e-05	0.00435	CbGpPWpGaD
Pemetrexed—Stomatitis—Methotrexate—colon cancer	2.68e-05	0.00117	CcSEcCtD
Pemetrexed—Urticaria—Fluorouracil—colon cancer	2.68e-05	0.00117	CcSEcCtD
Pemetrexed—Methotrexate—ABCB1—colon cancer	2.67e-05	0.0289	CrCbGaD
Pemetrexed—Conjunctivitis—Methotrexate—colon cancer	2.67e-05	0.00117	CcSEcCtD
Pemetrexed—Anaemia—Capecitabine—colon cancer	2.67e-05	0.00116	CcSEcCtD
Pemetrexed—Body temperature increased—Fluorouracil—colon cancer	2.66e-05	0.00116	CcSEcCtD
Pemetrexed—Hypersensitivity—Vincristine—colon cancer	2.66e-05	0.00116	CcSEcCtD
Pemetrexed—TYMS—E2F transcription factor network—CDKN1A—colon cancer	2.62e-05	0.00423	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	2.6e-05	0.00421	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Methotrexate—colon cancer	2.6e-05	0.00113	CcSEcCtD
Pemetrexed—Hypersensitivity—Irinotecan—colon cancer	2.59e-05	0.00113	CcSEcCtD
Pemetrexed—Asthenia—Vincristine—colon cancer	2.59e-05	0.00113	CcSEcCtD
Pemetrexed—Syncope—Capecitabine—colon cancer	2.59e-05	0.00113	CcSEcCtD
Pemetrexed—Leukopenia—Capecitabine—colon cancer	2.58e-05	0.00113	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—colon cancer	2.57e-05	0.00112	CcSEcCtD
Pemetrexed—DCK—Metabolism—CHST5—colon cancer	2.54e-05	0.00411	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ODC1—colon cancer	2.54e-05	0.00411	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Capecitabine—colon cancer	2.54e-05	0.00111	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	2.53e-05	0.0041	CbGpPWpGaD
Pemetrexed—Asthenia—Irinotecan—colon cancer	2.53e-05	0.0011	CcSEcCtD
Pemetrexed—Hypertension—Capecitabine—colon cancer	2.49e-05	0.00109	CcSEcCtD
Pemetrexed—TYMS—E2F transcription factor network—EP300—colon cancer	2.49e-05	0.00402	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—MYC—colon cancer	2.49e-05	0.00402	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Fluorouracil—colon cancer	2.48e-05	0.00108	CcSEcCtD
Pemetrexed—Diarrhoea—Vincristine—colon cancer	2.47e-05	0.00108	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—colon cancer	2.47e-05	0.00108	CcSEcCtD
Pemetrexed—Myalgia—Capecitabine—colon cancer	2.46e-05	0.00107	CcSEcCtD
Pemetrexed—Arthralgia—Capecitabine—colon cancer	2.46e-05	0.00107	CcSEcCtD
Pemetrexed—Chest pain—Capecitabine—colon cancer	2.46e-05	0.00107	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—colon cancer	2.45e-05	0.00107	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	2.44e-05	0.00107	CcSEcCtD
Pemetrexed—DHFR—Disease—LGR5—colon cancer	2.44e-05	0.00394	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CHST5—colon cancer	2.44e-05	0.00394	CbGpPWpGaD
Pemetrexed—Urinary tract disorder—Methotrexate—colon cancer	2.44e-05	0.00106	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—colon cancer	2.42e-05	0.00106	CcSEcCtD
Pemetrexed—Diarrhoea—Irinotecan—colon cancer	2.41e-05	0.00105	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	2.4e-05	0.00387	CbGpPWpGaD
Pemetrexed—Dizziness—Vincristine—colon cancer	2.39e-05	0.00104	CcSEcCtD
Pemetrexed—Pruritus—Fluorouracil—colon cancer	2.38e-05	0.00104	CcSEcCtD
Pemetrexed—Oedema—Capecitabine—colon cancer	2.36e-05	0.00103	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	2.35e-05	0.0038	CbGpPWpGaD
Pemetrexed—Infection—Capecitabine—colon cancer	2.34e-05	0.00102	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—colon cancer	2.33e-05	0.00102	CcSEcCtD
Pemetrexed—Dizziness—Irinotecan—colon cancer	2.33e-05	0.00102	CcSEcCtD
Pemetrexed—Shock—Capecitabine—colon cancer	2.32e-05	0.00101	CcSEcCtD
Pemetrexed—Nervous system disorder—Capecitabine—colon cancer	2.31e-05	0.00101	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—colon cancer	2.31e-05	0.00101	CcSEcCtD
Pemetrexed—Diarrhoea—Fluorouracil—colon cancer	2.31e-05	0.00101	CcSEcCtD
Pemetrexed—Thrombocytopenia—Capecitabine—colon cancer	2.31e-05	0.00101	CcSEcCtD
Pemetrexed—Vomiting—Vincristine—colon cancer	2.3e-05	0.001	CcSEcCtD
Pemetrexed—Skin disorder—Capecitabine—colon cancer	2.29e-05	0.000999	CcSEcCtD
Pemetrexed—Rash—Vincristine—colon cancer	2.28e-05	0.000995	CcSEcCtD
Pemetrexed—Dermatitis—Vincristine—colon cancer	2.28e-05	0.000994	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	2.27e-05	0.00368	CbGpPWpGaD
Pemetrexed—Anorexia—Capecitabine—colon cancer	2.25e-05	0.00098	CcSEcCtD
Pemetrexed—Vomiting—Irinotecan—colon cancer	2.24e-05	0.000977	CcSEcCtD
Pemetrexed—Dizziness—Fluorouracil—colon cancer	2.23e-05	0.000973	CcSEcCtD
Pemetrexed—Rash—Irinotecan—colon cancer	2.22e-05	0.000969	CcSEcCtD
Pemetrexed—Dermatitis—Irinotecan—colon cancer	2.22e-05	0.000968	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—TP53—colon cancer	2.21e-05	0.00358	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—colon cancer	2.21e-05	0.00357	CbGpPWpGaD
Pemetrexed—Alopecia—Methotrexate—colon cancer	2.18e-05	0.000952	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—CDKN1A—colon cancer	2.17e-05	0.00352	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—MYC—colon cancer	2.17e-05	0.00351	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MYC—colon cancer	2.16e-05	0.00349	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—ABCB1—colon cancer	2.15e-05	0.00348	CbGpPWpGaD
Pemetrexed—Malnutrition—Methotrexate—colon cancer	2.15e-05	0.000938	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—colon cancer	2.15e-05	0.000938	CcSEcCtD
Pemetrexed—Nausea—Vincristine—colon cancer	2.15e-05	0.000937	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Capecitabine—colon cancer	2.15e-05	0.000937	CcSEcCtD
Pemetrexed—Vomiting—Fluorouracil—colon cancer	2.14e-05	0.000935	CcSEcCtD
Pemetrexed—Rash—Fluorouracil—colon cancer	2.13e-05	0.000928	CcSEcCtD
Pemetrexed—Dermatitis—Fluorouracil—colon cancer	2.12e-05	0.000927	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—colon cancer	2.1e-05	0.000918	CcSEcCtD
Pemetrexed—Dyspnoea—Capecitabine—colon cancer	2.1e-05	0.000917	CcSEcCtD
Pemetrexed—Nausea—Irinotecan—colon cancer	2.09e-05	0.000912	CcSEcCtD
Pemetrexed—Dyspepsia—Capecitabine—colon cancer	2.07e-05	0.000905	CcSEcCtD
Pemetrexed—Decreased appetite—Capecitabine—colon cancer	2.05e-05	0.000894	CcSEcCtD
Pemetrexed—DHFR—Metabolism—ODC1—colon cancer	2.04e-05	0.0033	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CHST5—colon cancer	2.04e-05	0.0033	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Capecitabine—colon cancer	2.03e-05	0.000888	CcSEcCtD
Pemetrexed—Fatigue—Capecitabine—colon cancer	2.03e-05	0.000886	CcSEcCtD
Pemetrexed—Constipation—Capecitabine—colon cancer	2.01e-05	0.000879	CcSEcCtD
Pemetrexed—Pain—Capecitabine—colon cancer	2.01e-05	0.000879	CcSEcCtD
Pemetrexed—Nausea—Fluorouracil—colon cancer	2e-05	0.000874	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—colon cancer	1.99e-05	0.000867	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Capecitabine—colon cancer	1.93e-05	0.000841	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—colon cancer	1.92e-05	0.000839	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—CDKN1A—colon cancer	1.9e-05	0.00307	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—colon cancer	1.89e-05	0.00306	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MLH1—colon cancer	1.89e-05	0.00306	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—colon cancer	1.88e-05	0.00305	CbGpPWpGaD
Pemetrexed—Urticaria—Capecitabine—colon cancer	1.87e-05	0.000817	CcSEcCtD
Pemetrexed—GART—Metabolism—ABCB1—colon cancer	1.86e-05	0.00301	CbGpPWpGaD
Pemetrexed—Body temperature increased—Capecitabine—colon cancer	1.86e-05	0.000813	CcSEcCtD
Pemetrexed—Abdominal pain—Capecitabine—colon cancer	1.86e-05	0.000813	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN1A—colon cancer	1.83e-05	0.00296	CbGpPWpGaD
Pemetrexed—GART—Metabolism—TYMS—colon cancer	1.83e-05	0.00296	CbGpPWpGaD
Pemetrexed—Chest pain—Methotrexate—colon cancer	1.83e-05	0.000798	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—colon cancer	1.83e-05	0.000798	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—colon cancer	1.83e-05	0.000798	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—APC—colon cancer	1.83e-05	0.00295	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	1.82e-05	0.000793	CcSEcCtD
Pemetrexed—DHFR—G1/S Transition—MYC—colon cancer	1.8e-05	0.00292	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—BUB1B—colon cancer	1.8e-05	0.00291	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ODC1—colon cancer	1.78e-05	0.00288	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CHST5—colon cancer	1.78e-05	0.00288	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—colon cancer	1.77e-05	0.00287	CbGpPWpGaD
Pemetrexed—Anaphylactic shock—Methotrexate—colon cancer	1.75e-05	0.000765	CcSEcCtD
Pemetrexed—DHFR—Disease—AXIN2—colon cancer	1.75e-05	0.00283	CbGpPWpGaD
Pemetrexed—Infection—Methotrexate—colon cancer	1.74e-05	0.00076	CcSEcCtD
Pemetrexed—Hypersensitivity—Capecitabine—colon cancer	1.74e-05	0.000757	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—colon cancer	1.72e-05	0.000751	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—colon cancer	1.72e-05	0.000749	CcSEcCtD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—ABCB1—colon cancer	1.7e-05	0.00276	CbGpPWpGaD
Pemetrexed—Skin disorder—Methotrexate—colon cancer	1.7e-05	0.000743	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—PPARG—colon cancer	1.69e-05	0.00274	CbGpPWpGaD
Pemetrexed—Asthenia—Capecitabine—colon cancer	1.69e-05	0.000738	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—colon cancer	1.67e-05	0.00073	CcSEcCtD
Pemetrexed—Pruritus—Capecitabine—colon cancer	1.67e-05	0.000727	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—colon cancer	1.65e-05	0.00267	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MLH1—colon cancer	1.65e-05	0.00267	CbGpPWpGaD
Pemetrexed—Diarrhoea—Capecitabine—colon cancer	1.61e-05	0.000703	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—BUB1B—colon cancer	1.61e-05	0.0026	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1A—colon cancer	1.6e-05	0.00259	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—colon cancer	1.6e-05	0.000697	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—MYC—colon cancer	1.57e-05	0.00254	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—BUB1B—colon cancer	1.57e-05	0.00254	CbGpPWpGaD
Pemetrexed—Dyspnoea—Methotrexate—colon cancer	1.56e-05	0.000682	CcSEcCtD
Pemetrexed—Dizziness—Capecitabine—colon cancer	1.56e-05	0.00068	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—colon cancer	1.55e-05	0.0025	CbGpPWpGaD
Pemetrexed—Dyspepsia—Methotrexate—colon cancer	1.54e-05	0.000674	CcSEcCtD
Pemetrexed—Decreased appetite—Methotrexate—colon cancer	1.52e-05	0.000665	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—colon cancer	1.52e-05	0.00246	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Methotrexate—colon cancer	1.51e-05	0.000661	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—colon cancer	1.51e-05	0.00066	CcSEcCtD
Pemetrexed—Pain—Methotrexate—colon cancer	1.5e-05	0.000654	CcSEcCtD
Pemetrexed—Vomiting—Capecitabine—colon cancer	1.5e-05	0.000654	CcSEcCtD
Pemetrexed—Rash—Capecitabine—colon cancer	1.49e-05	0.000648	CcSEcCtD
Pemetrexed—Dermatitis—Capecitabine—colon cancer	1.48e-05	0.000648	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—colon cancer	1.43e-05	0.000626	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—BUB1B—colon cancer	1.4e-05	0.00227	CbGpPWpGaD
Pemetrexed—Nausea—Capecitabine—colon cancer	1.4e-05	0.000611	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—colon cancer	1.39e-05	0.000608	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—colon cancer	1.39e-05	0.000605	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—colon cancer	1.39e-05	0.000605	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	1.39e-05	0.00224	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TYMS—colon cancer	1.38e-05	0.00223	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—colon cancer	1.33e-05	0.00214	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PPARG—colon cancer	1.3e-05	0.0021	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ABCB1—colon cancer	1.29e-05	0.00209	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Methotrexate—colon cancer	1.29e-05	0.000564	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.29e-05	0.00208	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—TYMS—colon cancer	1.27e-05	0.00205	CbGpPWpGaD
Pemetrexed—Asthenia—Methotrexate—colon cancer	1.26e-05	0.000549	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.25e-05	0.00203	CbGpPWpGaD
Pemetrexed—Pruritus—Methotrexate—colon cancer	1.24e-05	0.000541	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.24e-05	0.00201	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TYMS—colon cancer	1.23e-05	0.002	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.21e-05	0.00196	CbGpPWpGaD
Pemetrexed—Diarrhoea—Methotrexate—colon cancer	1.2e-05	0.000524	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—colon cancer	1.16e-05	0.000506	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.15e-05	0.00186	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.12e-05	0.00181	CbGpPWpGaD
Pemetrexed—Vomiting—Methotrexate—colon cancer	1.11e-05	0.000487	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—EP300—colon cancer	1.11e-05	0.00179	CbGpPWpGaD
Pemetrexed—Rash—Methotrexate—colon cancer	1.11e-05	0.000483	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—colon cancer	1.1e-05	0.000482	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.09e-05	0.00177	CbGpPWpGaD
Pemetrexed—Nausea—Methotrexate—colon cancer	1.04e-05	0.000455	CcSEcCtD
Pemetrexed—GART—Metabolism—PTGS2—colon cancer	1.02e-05	0.00165	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ABCB1—colon cancer	1.01e-05	0.00163	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1e-05	0.00162	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1e-05	0.00162	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—TYMS—colon cancer	9.89e-06	0.0016	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	9.83e-06	0.00159	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FGFR3—colon cancer	9.44e-06	0.00153	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	9.28e-06	0.0015	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PPARG—colon cancer	8.99e-06	0.00145	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—APC—colon cancer	8.66e-06	0.0014	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	8.53e-06	0.00138	CbGpPWpGaD
Pemetrexed—GART—Metabolism—EP300—colon cancer	8.49e-06	0.00137	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	8.25e-06	0.00133	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—BRAF—colon cancer	8.14e-06	0.00132	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—colon cancer	7.92e-06	0.00128	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—colon cancer	7.07e-06	0.00114	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARG—colon cancer	7e-06	0.00113	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	6.97e-06	0.00113	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—colon cancer	6.95e-06	0.00112	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—colon cancer	6.72e-06	0.00109	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ABCB1—colon cancer	6.72e-06	0.00109	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TYMS—colon cancer	6.6e-06	0.00107	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—colon cancer	6.58e-06	0.00106	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EP300—colon cancer	6.4e-06	0.00103	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—colon cancer	6.28e-06	0.00102	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—colon cancer	6.21e-06	0.001	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—colon cancer	6.06e-06	0.00098	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—colon cancer	6.01e-06	0.000972	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—colon cancer	5.89e-06	0.000952	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—EP300—colon cancer	5.88e-06	0.000951	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—colon cancer	5.87e-06	0.000948	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—colon cancer	5.75e-06	0.00093	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EP300—colon cancer	5.72e-06	0.000925	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EP300—colon cancer	5.58e-06	0.000902	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—colon cancer	5.57e-06	0.000901	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—colon cancer	5.51e-06	0.000891	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EP300—colon cancer	5.47e-06	0.000885	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—colon cancer	5.42e-06	0.000877	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ABCB1—colon cancer	5.4e-06	0.000873	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SRC—colon cancer	5.32e-06	0.00086	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMS—colon cancer	5.3e-06	0.000857	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—colon cancer	5.24e-06	0.000848	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—colon cancer	5.13e-06	0.000829	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRAS—colon cancer	5.12e-06	0.000828	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FGFR3—colon cancer	5.06e-06	0.000818	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EP300—colon cancer	4.99e-06	0.000807	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—colon cancer	4.98e-06	0.000806	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—colon cancer	4.86e-06	0.000786	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—colon cancer	4.77e-06	0.000771	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFB1—colon cancer	4.76e-06	0.000769	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ABCB1—colon cancer	4.71e-06	0.000762	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARG—colon cancer	4.67e-06	0.000756	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—colon cancer	4.66e-06	0.000754	CbGpPWpGaD
Pemetrexed—DHFR—Disease—APC—colon cancer	4.65e-06	0.000751	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—EP300—colon cancer	4.58e-06	0.000741	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—colon cancer	4.41e-06	0.000712	CbGpPWpGaD
Pemetrexed—DHFR—Disease—BRAF—colon cancer	4.37e-06	0.000706	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—colon cancer	4.35e-06	0.000704	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—colon cancer	4.35e-06	0.000703	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—colon cancer	4.09e-06	0.000662	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—colon cancer	4.05e-06	0.000655	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARG—colon cancer	3.76e-06	0.000607	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—colon cancer	3.74e-06	0.000606	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—colon cancer	3.68e-06	0.000594	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—colon cancer	3.57e-06	0.000577	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—colon cancer	3.55e-06	0.000575	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—colon cancer	3.53e-06	0.00057	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—colon cancer	3.39e-06	0.000548	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—colon cancer	3.31e-06	0.000535	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARG—colon cancer	3.28e-06	0.00053	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—colon cancer	3.16e-06	0.00051	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—colon cancer	3.08e-06	0.000499	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—EP300—colon cancer	3.06e-06	0.000494	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—colon cancer	2.95e-06	0.000478	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EP300—colon cancer	2.93e-06	0.000474	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SRC—colon cancer	2.85e-06	0.000461	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—colon cancer	2.77e-06	0.000448	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRAS—colon cancer	2.74e-06	0.000444	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—colon cancer	2.58e-06	0.000417	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—colon cancer	2.56e-06	0.000413	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFB1—colon cancer	2.55e-06	0.000412	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—colon cancer	2.5e-06	0.000404	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—EP300—colon cancer	2.46e-06	0.000397	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—colon cancer	2.36e-06	0.000382	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—colon cancer	2.26e-06	0.000366	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—colon cancer	2.17e-06	0.000351	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—EP300—colon cancer	2.14e-06	0.000347	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—colon cancer	2.01e-06	0.000325	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—colon cancer	1.85e-06	0.000299	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—colon cancer	1.82e-06	0.000294	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—colon cancer	1.77e-06	0.000287	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—colon cancer	1.59e-06	0.000256	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—colon cancer	1.48e-06	0.00024	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—colon cancer	1.3e-06	0.00021	CbGpPWpGaD
